4.05Open4.05Pre Close0 Volume20 Open Interest95.00Strike Price0.00Turnover274.08%IV63.76%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry4.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0419Delta0.0005Gamma61.97Leverage Ratio-0.3219Theta-0.0088Rho-2.60Eff Leverage0.0580Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet